The patch effectively promotes hair growth for alopecia areata without pain.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
5 citations
,
December 2015 in “PubMed” Some gonadal hormone drugs can block filovirus entry into cells.
April 2020 in “Dermatology and therapy”
September 2022 in “Hair transplant forum international” JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
April 2023 in “International Journal of Research in Dermatology” Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
7 citations
,
January 2009 in “DOAJ (DOAJ: Directory of Open Access Journals)” D-004 did not harm sperm cells in mice.
December 2024 in “Cureus” Baricitinib treatment for alopecia universalis can cause hair regrowth with unexpected whitening.
66 citations
,
September 1982 in “Biochemical Pharmacology” Liver enzyme helps minoxidil work better for blood vessel relaxation.
7 citations
,
April 2006 in “Experimental Neurology” Finasteride blocks deoxycorticosterone's anticonvulsant effects in infant rats, but indomethacin doesn't.
23 citations
,
September 2019 in “Journal of The American Academy of Dermatology” Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
4 citations
,
January 1996 in “PubMed”
October 2023 in “The Cochrane library” The medicine baricitinib was found to notably improve hair regrowth in alopecia areata, but more research is needed on its side effects and other treatments.
21 citations
,
March 2003 in “Acta Dermato Venereologica” Tacalcitol ointment effectively improves bilateral nevus comedonicus.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
5 citations
,
May 2022 in “Clinical & Experimental Metastasis” Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.
255 citations
,
October 1985 in “The Journal of Clinical Endocrinology & Metabolism” Spironolactone treatment increases the amount of testosterone available in the body.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
July 2025 in “Derecho y cambio social.” Policosanol biorefining shows promise for heart health, needing better academic-industrial collaboration.
60 citations
,
May 2006 in “Journal of Neurochemistry” Social isolation makes rats more sensitive to alcohol's effects on the brain.
6 citations
,
April 2004 in “Journal of Enzyme Inhibition and Medicinal Chemistry” New progesterone-based compounds can block male hormones.
49 citations
,
April 2003 in “Biomaterials” Bismuth subgallate and borneol together improve skin wound healing better than when used separately or compared to other treatments.
January 2020 in “Nasza Dermatologia Online” A mixture of Dijon mustard, turmeric powder, and linseed oil can effectively treat alopecia barbae.
31 citations
,
January 1989 in “The Prostate/The prostate” Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.
March 2024 in “International journal of pharmaceutical chemistry and analysis (Print)” Betulin may help treat hair loss caused by testosterone.
May 2024 in “KIU journal of health science” Kolaviron and quercetin may help treat prostate issues.
1 citations
,
April 2009 in “Journal of Intellectual Property Law & Practice” UK courts and the European Patent Office are now more open to granting patents for new dosage regimes.